Meeting
2022 ASCO Annual Meeting
Adjuvant abemaciclib for high-risk early breast cancer (EBC): Factors increasing the rate of treatment discontinuations in monarchE.
Authors
Sara M. Tolaney
Dana-Farber Cancer Institute, Boston, MA
Sara M. Tolaney , Stephen R.D. Johnston , Ran Wei , Valerie AM Andre , Ashwin Shahir , Nadia Harbeck , Miguel Martin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT03155997
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 527)
DOI
10.1200/JCO.2022.40.16_suppl.527
Abstract #
527
Poster Bd #
299
Abstract Disclosures
Similar Posters
First Author: Oleg Gluz
Poster
2018 ASCO Annual Meeting
Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial.
First Author: Wolfgang Janni
Poster
2017 ASCO Annual Meeting
Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers.
First Author: Jane Bayani
Poster
2024 ASCO Genitourinary Cancers Symposium
Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
First Author: Joseph M Jacob